Trial Profile
A Phase 2, Open-Label Study To Evaluate The Efficacy And Safety Of Lenalidomide In Combination With Cetuximab In Pretreated Subjects With K-Ras Mutant Metastatic Colorectal Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cetuximab
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 06 Oct 2021 This trial has been completed in France ( global end of the trial 2011-01-25 ) as per European Clinical Trials Database.
- 17 Mar 2012 This trial has been completed in Germany, Belgium, Sweden, Italy.
- 11 Feb 2011 Planned end date changed from 1 Dec 2017 to 1 Jan 2011 as reported by ClinicalTrials.gov.